Abstract: The present invention provides an artificial nuclease comprising a DNA-binding domain and a function domain linked to each other via a polypeptide consisting of 35 to 55 amino acid residues wherein amino acid residues at two sites in a DNA-binding module contained in a DNA-binding domain exhibit a mode of repetition that is different for every four DNA-binding modules; a vector for expressing said artificial nuclease; a vector library for preparing said vector; and a vector set for preparing said vector library.

Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

Abstract: The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

Abstract: The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The stent graft (10) comprises a cylinder comprising a graft material in the form of a film and a stent that supports the cylinder. Further, the stent graft (10) is inserted within a region from the ascending aorta to the sinus of valsalva, and the stent graft comprises cylindrical body section (11) arranged in the ascending aorta and the sinus of valsalva section (12) arranged in the sinus of valsalva and having an inner diameter larger than that of the body section (11).

Abstract: Novel and effective anti-fibrosis agents are obtained. An anti-fibrosis agent containing an antagonist for integrin ?8?1 is used. In addition, used is an antagonist containing an anti-integrin ?8?1 antibody that specifically binds to at least one amino acid in a cap subdomain of an integrin ?8 chain and a periphery thereof. Also, used is an anti-fibrosis agent containing an anti-integrin ?8?1 antibody that specifically binds to R120 of an integrin ?8 chain and a periphery thereof or S132 and a periphery thereof. Note that the above antagonists may each be an anti-integrin ?8?1 antibody capable of binding to any of integrins ?8?1 derived from a human, mouse, and rat.

Abstract: An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

Abstract: [Problem to be Solved] It is intended to provide a fusion polypeptide that regulates the transcription of a target gene. [Solution] The present inventors have provided a fusion polypeptide comprising: a cell-penetrating peptide; a DNA-binding polypeptide; and a transcriptional regulator.

Abstract: Semiconductor devices each include: a semiconductor substrate that contains beta-gallium oxide and has a first conductivity type; a first semiconductor region that contains beta-gallium oxide, has the first conductivity type, and is provided on an upper side of the semiconductor substrate; a second semiconductor region that contains beta-gallium oxide, has a second conductivity type, and is provided on an upper side of a part of the first semiconductor region; and a third semiconductor region that contains beta-gallium oxide, has the first conductivity type, and is provided on an upper side of a part of the second semiconductor region. When the first conductivity type is an n-type and the second conductivity type is a p-type, the second semiconductor region further contains a band gap control element. The band gap control element is selected from a group of boron, aluminum, and indium.

Abstract: The present invention provides a method for purifying an intended substance, a kit for purifying the intended substance, and a silicon oxide-binding tag for use in the method and the kit. In the present invention, a complex of a silicon oxide-binding tag and a substance is caused to specifically bind to silicon oxide in a solution for binding, to which solution no salt is added, and binding between the silicon oxide-binding tag and the silicon oxide is broken with use of arginine.

Abstract: The present invention provides a method for purifying an intended substance, a kit for purifying the intended substance, and a silicon oxide-binding tag for use in the method and the kit. In the present invention, a complex of a silicon oxide-binding tag and a substance is caused to specifically bind to silicon oxide in a solution for binding, to which solution no salt is added, and binding between the silicon oxide-binding tag and the silicon oxide is broken with use of arginine.

Abstract: The present invention provides an artificial nuclease comprising a DNA-binding domain and a function domain linked to each other via a polypeptide consisting of 35 to 55 amino acid residues wherein amino acid residues at two sites in a DNA-binding module contained in a DNA-binding domain exhibit a mode of repetition that is different for every four DNA-binding modules; a vector for expressing said artificial nuclease; a vector library for preparing said vector; and a vector set for preparing said vector library.

Abstract: The present invention provides an artificial nuclease comprising a DNA-binding domain and a function domain linked to each other via a polypeptide consisting of 35 to 55 amino acid residues wherein amino acid residues at two sites in a DNA-binding module contained in a DNA-binding domain exhibit a mode of repetition that is different for every four DNA-binding modules; a vector for expressing said artificial nuclease; a vector library for preparing said vector; and a vector set for preparing said vector library.

Abstract: The present invention provides an artificial nuclease comprising a DNA-binding domain and a function domain linked to each other via a polypeptide consisting of 35 to 55 amino acid residues wherein amino acid residues at two sites in a DNA-binding module contained in a DNA-binding domain exhibit a mode of repetition that is different for every four DNA-binding modules; a vector for expressing said artificial nuclease; a vector library for preparing said vector; and a vector set for preparing said vector library.

Abstract: Provided include a human IgE antibody that binds to a sweat allergy antigen protein and a human high-affinity IgE receptor but does not induce degranulation in a reaction with the sweat allergy antigen protein, and a composition for treatment or diagnosis of sweat allergy comprising the same.

Abstract: Provided is a gas storing mask which, with a simple configuration, allows a reduction in feeling of discomfort given to a patient. An oxygen delivering mask (1a) includes a first sheet (2) and a second sheet (3), oxygen supplied from outside the oxygen delivering mask (1a) being stored in a gas storing part (4) formed between the first sheet (2) and the second sheet (3).

Abstract: A wind power generation system including a power generation unit having an elastically deformable base material in a shape of a longitudinal flat plate and a piezoelectric element disposed on the base material, and which generates electricity as the power generation unit is vibrated; the piezoelectric element is repeatedly bent and deformed by the vibration and stacked on the base material, the wind power generation system being configured to include a tension adjusting device that, when a wind speed is increased, moves the movable member to increase a tensile force that pulls the power generation unit in the longitudinal direction, and the tension adjusting device being a lift generating member that is formed integrally with the movable member so as to be extended and to have wing shape to both sides of the movable member and that moves the movable member based on lift generated according to the wind speed.